Search results
Feb 28, 2017 · With these words, Emil Behring (1854 to 1917) and Shibasaburo Kitasato (1853 to 1931) began their groundbreaking paper on diphtheria and tetanus immunity in experimental animals . The study demonstrated that sera from rabbits infected with Clostridium tetani conferred protection to naive mice against live tetanus bacilli and against tetanus toxin.
Apr 10, 2017 · Arguably, the three most important were: the paper he published in 1890 with Shibasaburo Kitasato on immunity to diphtheria and tetanus in experimental animals 1; his paper on immunity against...
- Stefan H. E. Kaufmann
- Kaufmann@mpiib-berlin.mpg.de
- 2017
People also ask
Who was Emil Behring and Shibasaburo Kitasato?
What did Kitasato and Behring do?
Who was Emil von Behring?
What did Emil von Behring discover?
In 1898, working with Koch's Japanese student Shibasaburo Kitasato, Behring showed that injections of serum from an animal with tetanus could confer immunity to the disease in other animals, and also that the same was true for diphtheria.
- Haas Lf
- 2001
In 1889, he became the first person to grow the tetanus bacillus in pure culture, and in 1890 cooperated with Emil von Behring in developing a serum therapy for tetanus using this pure culture. He also worked on antitoxins for diphtheria and anthrax .
Apr 10, 2017 · Arguably, the three most important were: the paper he published in 1890 with Shibasaburo Kitasato on immunity to diphtheria and tetanus in experimen tal animals1; his paper on immunity against...
- Stefan H. E. Kaufmann
- 2017
In 1885 Kitasato moved to Berlin to join the laboratory of German bacteriologist Robert Koch. There, with Emil von Behring, he studied tetanus and diphtheria, two bacterial infections that cause symptoms through the secretion of toxins.
May 20, 2024 · In 1890, working with Shibasaburo Kitasato, Behring showed that injections of blood serum from an animal suffering from tetanus could confer immunity to the disease in other animals. Behring found that the same was true for diphtheria and this led to the development of a diphtheria antitoxin for human patients, in collaboration with Paul Ehrlich.
